At the annual meeting of the American Academy of Allergy and Immunology, attendees were discussing the lack of therapy available to peanut allergy sufferers.
There is currently an ongoing blind trial, involving 29, under sixteen all with a history of immunoglobulin E medicated peanut allergy.
Although in its very early stages, data shows that when receiving controlled peanut protein, the participants had a slight lessening of their symptoms.
In the placebo managed research, the children had IgE levels of more than 15 KU/L. Some have already taken part in a peanut challenge whilst nearly twenty have actually finished the treatment part of the study.
Of the latter only slight symptoms were experienced such as itching and light cases of hives or stomach pain. The drug, epinephrine, was only required by one individual who had received the placebo.
Stacie Jones MD, the professor of pediatrics in Little Rock, Arkansas admits there is still a lot of research that needs to be carried out. Speaking at the recent meeting, she said that the future focus will be on immunology and the mechanics linked to it.
Results from the food challenge part of the study showed that those receiving oral therapy could afterwards tolerate twelve more actual peanuts than participants that had the placebo based treatment.
Furthermore, the level of tolerance was much higher in the oral group compared to those in the other.
All interesting results are a great base for future work in this crucial area that could make a real difference for too many people’s lives.